



November 9, 2016

## Sage Therapeutics to Present at the Stifel 2016 Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the Stifel 2016 Healthcare Conference at 11:00 AM ET on Wednesday, November 16, 2016 in New York, NY.

A live webcast of the presentation can be accessed on the investor page of Sage's website at [investor.sagerx.com](http://investor.sagerx.com). A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

### About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20161109006142/en/>

#### Investor Contact:

Sage Therapeutics  
Paul Cox, 617-299-8377  
[paul.cox@sagerx.com](mailto:paul.cox@sagerx.com)

or

#### Media Contact:

Suda Communications LLC  
Maureen L. Suda, 585-387-9248  
[maureen.suda@sagerx.com](mailto:maureen.suda@sagerx.com)

Source: Sage Therapeutics

News Provided by Acquire Media